Interindividual and intraindividual variability in labetalol pharmacokinetics. 1988

W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota 55415.

The between-subject and within-subject variability in the pharmacokinetics of labetalol at steady state were determined. Sixteen nonobese normal volunteers (mean age, 27 years) received five different formulations of labetalol orally on five different occasions every 12 hours for five doses. A 7-day washout separated each administration phase. Plasma concentration-time data for labetalol were obtained over the 24-hour period after the fifth dose in each phase. Labetalol concentrations in plasma were measured using high-performance liquid chromatography (HPLC). Pharmacokinetic parameters for each subject after each study phase were estimated. The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability. Considerable intraindividual variability in each of the pharmacokinetic parameters was also observed. These data indicate that a larger number of subjects will be required to detect "significant" differences in the disposition of labetalol.

UI MeSH Term Description Entries
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D008297 Male Males
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
January 1980, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
August 1988, Clinical pharmacology and therapeutics,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
January 2009, Drug metabolism reviews,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
July 2014, Medical mycology,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
July 1983, Clinical pharmacology and therapeutics,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
January 2005, Journal of clinical pharmacology,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
April 1992, Journal of clinical pharmacology,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
November 1989, [Rinsho ketsueki] The Japanese journal of clinical hematology,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
January 2000, Cancer chemotherapy and pharmacology,
W M Awni, and D J Skaar, and M H Schwenk, and M A Sirgo, and J R Plachetka, and G R Matzke
February 2009, International journal of pharmaceutics,
Copied contents to your clipboard!